Monthly research recap
DMT research: September 2026
What September 2026's 12 new studies found, synthesized from the papers below. All DMT research →
The synthesis
Synthesized from 12 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for DMT, dimethyltryptamine, N,N-DMT, then ranked by relevance.
Research indexed to September 2026 on DMT and related compounds is dominated by mechanistic and pharmacological work rather than clinical efficacy trials. Across EEG and fMRI studies, DMT reliably altered cortical dynamics—increasing signal complexity, reducing connectivity and network segregation, and shifting microstate sequences—with several measures tracking subjective intensity. Preclinical studies of 5-MeO-DMT found rapid antidepressant-like effects in rodents that depended on dose, administration context, and both 5-HT1A and 5-HT2A receptors, but these are animal models and do not establish human antidepressant efficacy. Human data remain limited to small samples, single-dose designs, and short follow-up, so durability, blinding integrity, and clinical benefit are largely unaddressed.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT 2026 | cross-sectional survey | Unclear | Describes self-reported health outcomes attributed to recent use of psilocybin, LSD, MDMA, ibogaine, and 5-MeO-DMT, but no specific outcomes, comparisons, or effect sizes are reported in the available text. | |
| Spiral brain dynamics track the temporal unfolding of subjective intensity during the N,N-dimethyltryptamine experience 2026 | within-subject fMRI study | Supports | DMT increased spiral vorticity and spatial spiral vorticity dispersion and reduced temporal irreversibility, with the largest changes in default mode, visual, frontoparietal, and dorsal attention networks; both vorticity measures tracked the temporal evolution of subjective intensity, and the strongest reorganization occurred during offset and recovery rather than at peak intensity. | |
| N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state 2026 | RCT | 25 | Supports | Compared with harmine alone and placebo, DMT/harmine reduced EEG microstate duration but increased microstate occurrence and complexity, and transition sequences became less random, which the authors interpret as increased metastability and signal diversity. |
| Toxicokinetics and analytical toxicology of four N, N-dimethyltryptamine derivatives studied in human in vitro systems and in vivo by means of zebrafish embryos. 2026 | in vitro and in vivo metabolism study | Supports | Four DMT derivatives were extensively metabolized mainly via N-demethylation and hydroxylation, with CYP1A2, CYP2D6, and FMO3 as the most active phase I enzymes and MAO-A contributing to DMT-THP metabolism; three derivatives had in vitro half-lives of 74-79 minutes while DMT-THP exceeded 180 minutes, and all showed plasma protein binding above 99 percent. | |
| 188. A single high-dose acute injection of 5-MeO-DMT reverses stress-induced anhedonia in rats 2026 | preclinical experimental study | Supports | A single 10 mg/kg dose of 5-MeO-DMT reversed chronic-mild-stress-induced anhedonia and normalized REM sleep reductions, while vehicle-treated stressed rats remained anhedonic; the authors argue anhedonia and learned helplessness are mediated by distinct mechanisms and that 5-MeO-DMT may act as a rapid-acting antidepressant targeting reward-related deficits. | |
| 515. Influence of the context of administration on 5-MeO-DMT-promoted antidepressant-like effects and neuroplasticity 2026 | preclinical experimental study | Mixed | 5-MeO-DMT at 0.5 mg/kg produced antidepressant-like effects in healthy and corticosterone-exposed mice when given in neutral or positive settings but not in a negative setting, which instead promoted anxiogenic-like responses; positive setting was associated with degradation of perineuronal nets around hippocampal parvalbumin interneurons correlating with improved behavioral z-scores. | |
| 805. Rapid Antidepressant-Like Effects of 5-MeO-DMT Require Both 5-HT 1A and 5-HT 2A Receptors 2026 | preclinical randomized controlled trial | Supports | 5-MeO-DMT (10 mg/kg) produced rapid antidepressant-like effects in the forced swim test that were blocked by both 5-HT1A and 5-HT2A receptor antagonism but not by 5-HT7 or sigma receptor antagonists, leading the authors to conclude both receptors are necessary and that head twitch responses can be dissociated from antidepressant-like efficacy. | |
| Exploratory Insights into 5-MeO-DMT Experiences on Reddit: A Thematic Analysis 2026 | qualitative study | 120 | Supports | Users described introspective, cathartic, and spiritually unifying experiences often viewed as transformative, reported individualized dosing and a distinct tolerance profile, and emphasized preparation, supportive settings, integration, awareness of serotonergic interactions, and harm reduction. |
| Higher signal diversity, network dysregulation, and increased well-being under DMT administration: An EEG study. 2026 | RCT | 13 | Supports | DMT reduced broadband EEG connectivity, network segregation, and efficiency, while Higuchi fractal dimension and permutation entropy showed band-specific complexity increases that correlated with subjective intensity; beta-to-alpha ratio and frontal alpha asymmetry also increased and correlated with perceived intensity, interpreted as greater neural unpredictability and emotional arousal consistent with the Entropic Brain theory. |
| A streamlined synthesis of 5-methoxy- N,N -dimethyltryptamine, bufotenin, and bufotenin prodrugs from melatonin 2026 | theoretical or philosophical paper | Supports | Argues that a streamlined, chromatography-free synthesis of 5-MeO-DMT and bufotenin from melatonin is feasible, achieving 76% overall yield for 5-MeO-DMT and 51% for bufotenin, and proposes candidate bufotenin prodrugs to enhance nanoformulation and blood-brain barrier uptake. | |
| Safety, pharmacokinetics, and pharmacodynamics of intravenously administered deuterated N,N-dimethyltryptamine (CYB004) in healthy volunteers. 2026 | RCT | Mixed | CYB004, a deuterated DMT analogue, produced psychedelic effects comparable to DMT at similar plasma concentrations but with a roughly two-fold longer half-life extending effects to about 40-60 minutes; deuteration did not reduce pharmacokinetic variability, high doses led to intense experiences and participant withdrawals, and lower doses showed an acceptable safety profile. | |
| The Role of Nutrition in Psychedelics Clinical Trials: Key Considerations and Recommendations for 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) 2026 | narrative review | Unclear | Proposes that nutritional status, diet, body composition, gut microbiota, and food-drug interactions may plausibly influence the pharmacokinetics, pharmacodynamics, efficacy, or safety of 5-MeO-DMT based on its serotonergic profile and indirect evidence, while noting direct clinical evidence is currently unavailable. |
Points of agreement
- Multiple independent EEG and fMRI studies report that DMT increases measures of neural signal complexity and diversity while reducing connectivity, network segregation, and efficiency.
- Several studies find that these neural changes correlate with subjective intensity, supporting a brain-experience coupling.
- Preclinical work consistently reports rapid antidepressant-like effects of 5-MeO-DMT in rodent stress and depression models.
- Rodent studies agree that 5-MeO-DMT's behavioral effects are dose-dependent and involve serotonergic receptor signaling.
Conflicts
- One preclinical study finds 5-MeO-DMT's antidepressant-like effects depend on administration context and can turn anxiogenic in a negative setting, whereas another reports robust antidepressant-like effects without manipulating context.
- The deuterated DMT analogue study reports acceptable safety at lower doses but intense experiences and participant withdrawals at high doses, indicating a narrow separation between desired and adverse effects.
Gaps
- No human clinical trial in this set tests DMT or 5-MeO-DMT antidepressant efficacy with clinical endpoints; antidepressant evidence is preclinical only.
- Durability of any therapeutic or neural effect beyond acute dosing is not established.
- Human samples are small (e.g., 13-25 participants) and mostly healthy volunteers, limiting generalizability to patient populations.
- Blinding integrity and expectancy effects are not addressed in the human psychedelic studies.
- Dose-response relationships in humans, optimal dosing, and long-term safety are largely uncharacterized.
- Direct clinical evidence on nutrition, diet, or food-drug interactions with 5-MeO-DMT is absent.